BAY-293 : KRAS-SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC)
Ravoxertinib : Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models
BAY-293 : KRAS-SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC)
Ravoxertinib : Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models